In 2008 it seemed like Enrique Reynaud had the world in his back pocket. A veteran professor of molecular biology at Mexico's largest and most important university, he was about to start his first company, Biohominis. It was a kind of Mexican 23andMe—a laboratory that could offer insight into a customer's genetic proclivity to hypertension, diabetes and other diseases.